John V. Heymach
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (47)
Supp Table 5. Flatiron Health-Foundation Medicine Clinicogenomic Database (FH-FMI CGDB) cohort characteristics, overall and stratified by treatment with chemotherapy along (Chemo), immune checkpoint inhibitor monotherapy (ICI), or combination ICI with chemotherapy (ICI-chemo)
Year:
2025
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.
Year:
2025
A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.
Year:
2025
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.
Year:
2025
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.
Year:
2025
Genomic summary metrics and HLA features of patients with long-term response (LTR), short-term response (STR), and progressive disease (PD) among patients with next-generation sequencing by MSK-IMPACT.
Year:
2025
Purpose: First-line treatment options for MET exon 14 skipping–mutant metastatic non–small cell lung cancer vary because of differences in drug approvals and clinical experience. This study investigates factors influencing outcomes with first-line MET tyrosine kinase inhibitors (TKI) versus immune checkpoint inhibitors (ICI) ± chemotherapy. Experimental Design: Clinicopathologic data were collected from patients with metastatic MET exon 14 skipping–mutant non–small cell lung cancer treated with first-line MET TKI or ICI ± chemotherapy at five centers. Primary endpoints were real-world progression-free survival (rwPFS) and overall survival (OS) to first-line MET TKI versus ICI ± chemotherapy. Subgroup analyses by clinical and tumor characteristics were performed. Results: Among 158 patients, 80 received MET TKI and 78 received ICI ± chemotherapy as first-line treatment. Baseline clinicopathologic features were balanced except for a higher proportion of patients with a history of smoking in the ICI ± chemotherapy group ( P = 0.03). With a median follow-up of 37.9 months, no difference was observed in rwPFS (HR, 0.85; P = 0.4) or OS (HR, 0.97; P = 0.9) with first-line MET TKI versus ICI ± chemotherapy. In subgroup analyses, first-line ICI ± chemotherapy improved rwPFS in PD-L1 ≥80% (HR, 0.50; P = 0.03), whereas MET TKI improved rwPFS (HR, 0.40; P = 0.005) and OS (HR, 0.49; P = 0.03) in PD-L1 P = 0.02) and OS (HR, 0.36; P = 0.03) in brain metastases and rwPFS (HR, 0.55; P = 0.01) in bone metastases. No significant differences were observed in the incidence of high-grade toxicity ( P = 0.9) or rates of permanent treatment discontinuation ( P = 0.2) between first-line MET TKI and ICI ± chemotherapy. Conclusions: First-line MET TKI improved outcomes in PD-L1
Year:
2025
Purpose: Patients with non–small cell lung cancer harboring EGFR mutations typically have significant clinical benefits from EGFR tyrosine kinase inhibitors (TKI) such as osimertinib. However, a residual population of drug-tolerant persister cells (DTPC) inevitably remains, which ultimately gives rise to fully drug-resistant cells (DRC). This study evaluates the activity of EGFR chimeric antigen receptor (CAR)–based therapies in this context. Experimental Design: We developed EGFR CAR T and CAR NK cells and evaluated their antitumor activity against parental cells, DTPC, and DRC in vitro and in vivo . We investigated the mechanisms regulating the sensitivity of DTPC and DRC to CAR T or CAR NK cells, including NK-activating ligands, TGF-β signaling, and EGFR surface levels. Additionally, we developed strategies that included galunisertib treatment and the expression of a dominant-negative TGF-β receptor II in CAR NK cells. Results: DTPC demonstrated increased sensitivity to both EGFR CAR T and CAR NK cells. DRC were relatively resistant to CAR T cells but more sensitive to CAR NK cells. DRC and DTPC had higher levels of natural cytotoxicity triggering receptor-3 and NKG2D ligands, which enhance the effectiveness of CAR NK cells. Elevated TGF-β levels in DRC impaired CAR function, but this was reversed by coexpression of galunisertib or dominant-negative TGF-β receptor II in CAR NK cells. Continued TKI treatment increased EGFR expression on DRC, possibly contributing to the improved killing activity seen with TKI/CAR combinations compared with CAR alone in TKI-resistant cells. Conclusions: EGFR-directed cellular therapies, particularly EGFR CAR NK cells, demonstrate activity against EGFR-mutant DTPC and DRC in vitro and in vivo , with enhanced activity observed when combined with EGFR TKI or TGF-β pathway blockade.
Year:
2025
Purpose: KRAS inhibitors are revolutionizing the treatment of non–small cell lung cancer (NSCLC), but clinico-genomic determinants of treatment efficacy warrant continued exploration. Experimental Design: Patients with advanced KRAS G12C -mutant NSCLC treated with adagrasib [KRYSTAL-1 (NCT03785249)] were included in the analysis. Pretreatment next-generation sequencing data were collected per protocol. HTG EdgeSeq Transcriptome Panel was used for gene expression profiling. Clinical endpoints included objective response, progression-free survival (PFS), and overall survival (OS). KRAS G12C -mutant NSCLC cell lines and xenograft models were used for sensitivity analyses and combination drug screens. Results: KEAP1 MUT and STK11 MUT were associated with shorter survival to adagrasib [ KEAP1 : PFS 4.1 vs. 9.9 months, HR 2.7, P P STK11 : PFS 4.2 vs. 11.0 months, HR 2.2, P P KEAP1 WT / STK11 WT status identified adagrasib-treated patients with significantly longer PFS (16.9 months) and OS (NR). Preclinical analyses further validate the association between KEAP1 loss of function and adagrasib resistance. Adagrasib and mTOR inhibitor combinations produced higher treatment efficacy in NSCLC models harboring STK11 and KEAP1 co-mutations. NRF2 HIGH signaling was associated with shorter survival to adagrasib (PFS: 4.2 vs. 8.4 months, HR 2.0, P = 0.02; OS: 6.5 vs. 19.0 months, HR 2.8, P KEAP1 WT NSCLC. KEAP1 WT / STK11 WT /NRF2 LOW status identified patients—32%—with longer survival to adagrasib (PFS 12.0 vs. 4.2 months, HR 0.2, P P Conclusions: KEAP1 , STK11 , and NRF2 status define patients with KRAS G12C -mutant NSCLC with markedly distinct outcomes to adagrasib. These results further support the use of genomic features—mutational and nonmutational—for the treatment selection of patients with KRAS G12C -mutant NSCLC.
Year:
2025
Supplementary Figure S7. Clinical outcomes to adagrasib monotherapy according to NRF2 score and STK11 co-mutation status in KEAP1 WT / KRAS G12C -mutant NSCLC patients.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (89)
Alessandro Di Federico
University of Bologna
Jennifer W Carlisle
Winship Cancer Institute of Emory University
Xiuning Le
The University of Texas MD Anderson Cancer Center
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
David Gerber
Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences
University of Texas Southwestern Medical Center
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Scott E. Kopetz
The University of Texas MD Anderson Cancer Center
Shunsuke Kondo
Professor
Tokyo Women's Medical University
Neal Akhave
Assistant Professor
The University of Texas MD Anderson Cancer Center
Christine Bestvina
Assistant Professor
University of Chicago Medicine
Sandip Patel
Associate Professor
Moores Cancer Center, UC San Diego Health
Marina Garassino
Prof
Università degli Studi di Torino
Heath Skinner
Professor & Chair
University of Pittsburgh
Mark Davis
Howard Hughes Medical Institute
Jacobi Hines
Assistant Professor
Northwestern Medicine
Steven Frank
The University of Texas MD Anderson Cancer Center
Ajay Sheshadri
Assistant Professor
The University of Texas MD Anderson Cancer Center
Lauren A. Byers
The University of Texas MD Anderson Cancer Center
Martin Edelman
Physician and Chair
Fox Chase Cancer Center
Alfredo Addeo
University Hospital of Geneva
Jeffrey N. Myers
The University of Texas MD Anderson Cancer Center
Curtis R. Pickering
The University of Texas MD Anderson Cancer Center
Qi Wang
The University of Texas MD Anderson Cancer Center
Samera Hamad
Assistant Professor
Cooper Medical School of Rowan University
Marjorie Zauderer
Section Chief, Hematology & Medical Oncology
New York Medical College
Michael A. Curran
Professor
The University of Texas MD Anderson Cancer Center
Yu Qian
The University of Texas MD Anderson Cancer Center
Mizuki Nishino
King’s College London
Petros Christopoulos
-
Phillip Pifer
Assistant Professor
West Virginia University Hospitals
Ken Lau
Associate Professor
Vanderbilt University School of Medicine
Charles Rudin
Memorial Sloan Kettering Cancer Center
Amy L Cummings
UCLA School of Medicine
Mehmet Altan
Associate Professor
The University of Texas MD Anderson Cancer Center
Andrew Futreal
Chair and Professor
The University of Texas MD Anderson Cancer Center
Giorgio V Scagliotti
Chair
University of Turin
james hicks
H Lee Moffitt Cancer Center and Research Institute
Deborah Schrag
Memorial Sloan Kettering Cancer Center
Mingjia Li
Assistant Professor
Ohio State University
Hai Tran
Associate Professor
The University of Texas MD Anderson Cancer Center
Bernard E. Weissman
University of North Carolina at Chapel Hill School of Medicine
Vlad Sandulache
Associate Professor
Baylor College of Medicine
Renata Ferrarotto
The University of Texas MD Anderson Cancer Center
Samir M. Hanash
The University of Texas MD Anderson Cancer Center
Collin Blakely
Assistant Professor
UCSF Medical Center
Bin Liu
The University of Texas MD Anderson Cancer Center
Matthias Scheffler
University Hospital Bonn
Chao Cheng
Associate Professor
Baylor College of Medicine
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Michael Frumovitz
Professor
The University of Texas MD Anderson Cancer Center
Matthew D. Hellmann
Weill Cornell Medical College
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
Heather Wakelee
Professor
Stanford University
Beth M. Beadle
Professor
Stanford University
Natalie Vokes
The University of Texas MD Anderson Cancer Center
LI SHEN
The University of Texas MD Anderson Cancer Center
Francesco Gelsomino
ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA
Anna Obenauf
Group leader
Research Institute of Molecular Pathology
Mara B. Antonoff
The University of Texas MD Anderson Cancer Center
Andrea De Giglio
University of Bologna
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Seyed Javad Moghaddam
Professor
The University of Texas MD Anderson Cancer Center
Alexandre Reuben
Assistant Professor
The University of Texas MD Anderson Cancer Center
Rafael Irizarry
Professor and Chair
Harvard University
Simon Heeke
Assistant Professor
The University of Texas MD Anderson Cancer Center
Yukina Shirai
Juntendo University
Muhammad Furqan
Professor
University of Oklahoma Health Sciences Center
Ying Ni
Assistant Professor
Case Western Reserve University
Catherine Shu
Columbia University Irving Medical Center
Ferdinandos Skoulidis
The University of Texas MD Anderson Cancer Center
Albrecht Stenzinger
-
Edwin J. Ostrin
Associate Professor
The University of Texas MD Anderson Cancer Center
Ken Chen
Professor
The University of Texas MD Anderson Cancer Center
Marcelo Negrao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Don L. Gibbons
The University of Texas MD Anderson Cancer Center
Humam Kadara
The University of Texas MD Anderson Cancer Center
Dwight H. Owen
Ohio State University
Jia Wu
Associate Professor
The University of Texas MD Anderson Cancer Center
YASIR ELAMIN
Assistant Professor
The University of Texas MD Anderson Cancer Center
Tao Wang
The University of Texas MD Anderson Cancer Center
Chad Vanderbilt
Associate Attending Pathologist
Memorial Sloan Kettering Cancer Center
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
Marcello Tiseo
University of Parma
ENRIQUETA FELIP
Head Thoracic Oncology Unit (After Competitive Exam)
Hospital Universitari Vall d'Hebron
Gilberto Lopes
Associate Professor
Sylvester Comprehensive Cancer Center
Sonia Patel
Life Science Research Professional
Stanford University School of Medicine
Abdullah Osman
Associate Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.